- UroToday Home
- Recent Abstracts
- Urologic Oncology
- Bladder Cancer
Conferences
APCCC Diagnostics 2025: False Positive PSMA PET: What to Know?
February 28, 2025
APCCC Diagnostics 2025: When to Assess Biology with a Re-Biopsy?
February 28, 2025
APCCC Diagnostics 2025: What Do We Expect from Monitoring in Metastatic Prostate Cancer?
February 28, 2025
APCCC Diagnostics 2025: PSA Relapse: When Do You Need to Act?
February 28, 2025
APCCC Diagnostics 2025: What Clinicians Need to Know from the PSMA RLT Selection PET?
February 28, 2025
APCCC Diagnostics 2025: What Do You Do with a Negative Scan: Treat Now or Later with a Positive Scan?
February 28, 2025
APCCC Diagnostics 2025: Biochemical Recurrence: When Do You Image?
February 28, 2025
APCCC Diagnostics 2025: Risk Stratification Using a Genomic Classifier for Localized Prostate Cancer: What Is the Added Value?
February 27, 2025
APCCC Diagnostics 2025: Which Prostate Cancer Risk Group System Is Most Useful for Today?
February 27, 2025
APCCC Diagnostics 2025: How Do You Diagnose Prostate Cancer? Molecular Tests at Diagnosis for Risk Stratification
February 27, 2025
ASCO GU 2025: Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer – What’s Next
February 18, 2025
Bladder Cancer: Upstaging and Risk Mitigation with Blue Light Cystoscopy in NMIBC Featured at ASCO GU 2025
February 18, 2025
ASCO GU 2025: Overcoming Challenges of Antibody Drug Conjugate Toxicity in Bladder Cancer
February 18, 2025
ASCO GU 2025: Targeting Bladder Cancer with Antibody Drug Conjugates
February 18, 2025